Experimental and clinical aspects of melatonin and clock genes in diabetes

Journal of Pineal Research

Volumn 59, Issue 1, 2015, Pages 1-23

  Peschke, Elmar ^a   Bähr, Ina ^b   Mühlbauer, Eckhard ^a  

^a Saxon Academy of Sciences   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

clock genes; experimental and clinical aspects; glucagon; insulin; melatonin; melatonin receptors; type 1 and type 2 diabetes

Indexed keywords

GLUCAGON; INDOLEAMINE; INSULIN; MELATONIN; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; REACTIVE OXYGEN METABOLITE;

ARTICLE; CIRCADIAN RHYTHM; DIABETES MELLITUS; GENE; GENE LOCUS; GENETIC RISK; GENETIC VARIABILITY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET; PANCREAS ISLET BETA CELL; SIGNAL TRANSDUCTION; SOMATOSTATINOMA; ANIMAL; EXPERIMENTAL DIABETES MELLITUS; GENETICS; METABOLISM;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; GLUCAGON; HUMANS; INSULIN; MELATONIN;

EID: 84934268769     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/jpi.12240     Document Type: Article

References (258)

1. Parhon CI,. Congrès d'Endocrinologie de Bucarest. 1939; Vol. I. p. 187.
2. Parhon CI, Potop I, Felix E, et al., Influenta epifisectomiei si a administrarii de extract epifisar asupra unor data metabolice privind mineralele (Ca, K, P, Si, Mg), lipidele, protidele si glucidele, la sobolanul alb adult. Stud Cercet Endocrinol 1952; 3: 321-329.
3. Milcou I, Nanu L, Marcean R,. De l'existence d'une hormone hypoglycémiante épiphysaire synergique de l'insuline. Ann Endocrinol 1957; 18: 612-620.
4. Milcou SM,. Role of epiphysis in carbohydrate metabolism. Journ Annu Diabetol Hotel Dieu 1968; 9: 163-180.
5. Milcu SM, Milcu I,. Über ein hypoglykämisch wirkendes Hormon in der Zirbeldrüse. Medizinische 1958; 17: 711-715.
6. Milcu I, Nanu L, Marcean R, et al., L'action de l'extrait pinéal et de la pinéalectomie sur le glycogène hépatique et musculaire après infusion prolongée de glucose. Stud Cercet Endocrinol 1963; 14: 651-655.
7. Milcou SM, Milcou I, Nanu L,. Le role de la glande pinéale dans le métabolisme des glucides. Ann Endocrinol (Paris) 1963; 24: 233-254.
8. Milcu I, Nanu L, Marcean R, et al., Research on the diabetogenic effects of epiphysectomy in the lamb. Stud Cercet Endocrinol 1964; 15: 507-513.
9. Milcu SM, Nanu-Ionescu L, Milcu I,. The effect of pinealectomy on plasma insulin in rats. In: The Pineal Gland., Wolstenholme GEW, Knight J, eds., Churchill Livingstone, Churchill Livingstone, Edinburgh and London, 1971; pp. 345-357.
10. Lerner AB, Case JD, Takahashi Y, et al., Isolation of melatonin, the pineal gland factor that lightens melanocytes. J Am Chem Soc 1958; 80: 2587.
11. Lerner AB, Case JD, Heinzelman RV,. Structure of melatonin. J Am Chem Soc 1959; 81: 6084-6092.
12. Diaz B, Blazquez E,. Effect of pinealectomy on plasma glucose, insulin and glucagon levels in the rat. Horm Metab Res 1986; 18: 225-229.
13. Mellado MC, Rodriguez MV, Diaz B, et al., Role of the pineal gland in the normal maintenance of circulating levels and of liver receptor concentrations of insulin and glucagon in the rat. In: Proceedings Workshop Pineal Gland., Reiter RJ, Blasques E, eds., Salamanca, Spain, 1986; pp. 52-56.
14. Rodriguez V, Mellado C, Alvarez E, et al., Effect of pinealectomy on liver insulin and glucagon receptor concentrations in the rat. J Pineal Res 1989; 6: 77-88.
15. Munoz Barragán L, Lõpez Gil JA, Toranzo D, et al., The pineal gland: a neuroendocrine "crossroad". In: Proceedings of the Workshop on the Pineal Gland., Reiter RJ, Blasques E, eds., Salamanca, Spain, 1986; pp. 57-61.
16. Munoz Barragán L, Toranzo D, Blázquez E, et al., Role of the pineal gland on insulin and glucagon release of control and diabetic rats. Diabetes 1983; 32: 141A.
17. Munoz Barragán L, Toranzo D, Blázquez E, et al., A radio-immunoanalytical and immunocytochemical study on A and B insular cells in response to pinealectomy or pineal denervation. Diabetologia 1984; 27: 313A.
18. De Lima LM, Dos Reis LC, De Lima MA,. Influence of the pineal gland on the physiology, morphometry and morphology of pancreatic islets in rats. Braz J Biol 2001; 61: 333-340.
19. Shima T, Chun SJ, Niijima A, et al., Melatonin suppresses hyperglycemia caused by intracerebroventricular injection of 2-deoxy-D-glucose in rats. Neurosci Lett 1997; 226: 119-122.
20. Conti A, Maestroni GJ,. Melatonin rhythms in mice: role in autoimmune and lymphoproliferative diseases. Ann N Y Acad Sci 1998; 840: 395-410.
21. Conti A, Maestroni GJ,. Role of the pineal gland and melatonin in the development of autoimmune diabetes in non-obese diabetic mice. J Pineal Res 1996; 20: 164-172.
22. Benson B, Miller CW, Sorrentino S,. Effects of blinding on blood glucose and serum insulin-like activity in rats. Tex Rep Biol Med 1971; 29: 513-525.
23. Burns JK,. Serum sodium and potassium and blood glucose levels in cynamolgus monkeys after administration of melatonin. J Physiol 1973; 232: 84P-85P.
24. Csaba G, Barath P,. Are Langerhan's islets influenced by the pineal body? Experientia 1971; 27: 962.
25. Csaba G, Nagy SU,. The regulatory role of the pineal gland on the thyroid gland, adrenal medulla and islets of Langerhans. Acta Biol Med Ger 1973; 31: 617-619.
26. Nanu-Ionescu L, Ionescu V,. La glande pinéale et le métabolisme de l'insuline. I. Le niveau sanguin de l'activité insulinique totale et de l′insuline "libre" et "liée" dans l'apinéalisme experimental. Stud Cercet Endocrinol 1969; 20: 237-243.
27. Nanu-Ionescu L, Marcean R,. La glande pinéale et le métabolisme de l'insuline. II. Les facteurs plasmatique anti-insuliniques dans l′apinéalisme expérimental. Rev Roum Endocrincol 1970; 2: 55-61.
28. Gorray KC, Quay WB,. Effects of pinealectomy and of sham-pinealectomy on blood glucose levels in the alloxan-diabetic rat. Horm Metab Res 1978; 10: 389-392.
29. Quay WB, Gorray KC,. Pineal effects on metabolism and glucose homeostasis: evidence for lines of humoral mediation of pineal influences on tumor growth. J Neural Transm 1980; 47: 107-120.
30. Rasmussen DD, Boldt BM, Wilkinson CW, et al., Daily melatonin administration at middle age suppresses male rat visceral fat, plasma leptin, and plasma insulin to youthful levels. Endocrinology 1999; 140: 1009-1012.
31. Wolden-Hanson T, Mitton DR, McCants RL, et al., Daily melatonin administration to middle-aged male rats suppresses body weight, intraabdominal adiposity, and plasma leptin and insulin independent of food intake and total body fat. Endocrinology 2000; 141: 487-497.
32. Rasmussen DD, Mitton DR, Larsen SA, et al., Aging-dependent changes in the effect of daily melatonin supplementation on rat metabolic and behavioral responses. J Pineal Res 2001; 31: 89-94.
33. Dhar M, Dayal SS, Ramesh Babu CS, et al., Effect of melatonin on glucose tolerance and blood glucose circadian rhythm in rabbits. Indian J Physiol Pharmacol 1983; 27: 109-117.
34. Cagnacci A, Arangino S, Renzi A, et al., Influence of melatonin administration on glucose tolerance and insulin sensitivity of postmenopausal women. Clin Endocrinol (Oxf) 2001; 54: 339-346.
35. Champney TH, Steger RW, Christie DS, et al., Alterations in components of the pineal melatonin synthetic pathway by acute insulin stress in the rat and Syrian hamster. Brain Res 1985; 338: 25-32.
36. Champney TH, Brainard GC, Richardson BA, et al., Experimentally-induced diabetes reduces nocturnal pineal melatonin content in the Syrian hamster. Comp Biochem Physiol A Comp Physiol 1983; 76: 199-201.
37. Boden G, Ruiz J, Urbain JL, et al., Evidence for a circadian rhythm of insulin secretion. Am J Physiol 1996; 271: E246-E252.
38. Champney TH, Holtorf AP, Craft CM, et al., Hormonal modulation of pineal melatonin synthesis in rats and Syrian hamsters: effects of streptozotocin-induced diabetes and insulin injections. Comp Biochem Physiol A Comp Physiol 1986; 83: 391-395.
39. O'Brien IA, Lewin IG, O'Hare JP, et al., Abnormal circadian rhythm of melatonin in diabetic autonomic neuropathy. Clin Endocrinol (Oxf) 1986; 24: 359-364.
40. John TM, Viswanathan M, George JC, et al., Influence of chronic melatonin implantation on circulating levels of catecholamines, growth hormone, thyroid hormones, glucose, and free fatty acids in the pigeon. Gen Comp Endocrinol 1990; 79: 226-232.
41. Lynch HJ, Hsuan M, Wurtman RJ,. Sympathetic neural control of indoleamine metabolism in the rat pineal gland. Adv Exp Med Biol 1975; 54: 93-114.
42. Tannenbaum MG, Reiter RJ, Vaughan MK, et al., Adrenalectomy prevents changes in rat pineal melatonin content and N-acetyltransferase activity induced by acute insulin stress. J Pineal Res 1987; 4: 395-402.
43. Mahata SK, Mandal A, Ghosh A,. Influence of age and splanchnic nerve on the action of melatonin in the adrenomedullary catecholamine content and blood glucose level in the avian group. J Comp Physiol B 1988; 158: 601-607.
44. Mahata SK,. Effect of insulin on serotonin, 5-hydroxyindole-acetic acid, norepinephrine, epinephrine and corticosterone contents in chick. Neurosci Lett 1991; 121: 115-118.
45. Maitra SK, Dey M, Dutta S, et al., Influences of graded dose of melatonin on the levels of blood glucose and adrenal catecholamines in male roseringed parakeets (Psittacula krameri) under different photoperiods. Arch Physiol Biochem 2000; 108: 444-450.
46. Maitra SK, Dey M, Dey R, et al., Influence of photoperiods on glycemic and adrenal catecholaminergic responses to melatonin administrations in adult male roseringed parakeets, Psittacula krameri Neumann. Indian J Exp Biol 2000; 38: 1111-1116.
47. Feldman JM, Lebovitz HE,. Structural determinants of indole amine action on in vitro insulin release. Endocrinology 1972; 91: 809-816.
48. Frankel BJ, Strandberg MJ,. Insulin release from isolated mouse islets in vitro: no effect of physiological levels of melatonin or arginine vasotocin. J Pineal Res 1991; 11: 145-148.
49. Bizot-Espiard JG, Double A, Cousin B, et al., Lack of melatonin effects on insulin action in normal rats. Horm Metab Res 1998; 30: 711-716.
50. Niijima A, Chun SJ, Shima T, et al., Effect of intravenous administration of melatonin on the efferent activity of the adrenal nerve. J Auton Nerv Syst 1998; 71: 134-138.
51. Peschke E, Muhlbauer E, Musshoff U, et al., Receptor (MT(1)) mediated influence of melatonin on cAMP concentration and insulin secretion of rat insulinoma cells INS-1. J Pineal Res 2002; 33: 63-71.
52. Stumpf I, Muhlbauer E, Peschke E,. Involvement of the cGMP pathway in mediating the insulin-inhibitory effect of melatonin in pancreatic beta-cells. J Pineal Res 2008; 45: 318-327.
53. Bahr I, Muhlbauer E, Albrecht E, et al., Evidence of the receptor-mediated influence of melatonin on pancreatic glucagon secretion via the Galphaq protein-coupled and PI3K signaling pathways. J Pineal Res 2012; 53: 390-398.
54. Peschke E, Fauteck JD, Musshoff U, et al., Evidence for a melatonin receptor within pancreatic islets of neonate rats: functional, autoradiographic, and molecular investigations. J Pineal Res 2000; 28: 156-164.
55. Kemp DM, Ubeda M, Habener JF,. Identification and functional characterization of melatonin Mel 1a receptors in pancreatic beta cells: potential role in incretin-mediated cell function by sensitization of cAMP signaling. Mol Cell Endocrinol 2002; 191: 157-166.
56. Muhlbauer E, Peschke E,. Evidence for the expression of both the MT1- and in addition, the MT2-melatonin receptor, in the rat pancreas, islet and beta-cell. J Pineal Res 2007; 42: 105-106.
57. Csernus VJ, Schally AV,. The dispersed cell superfusion system. In: Neuroendocrine Research Methods., Greenstein BD, ed., Harwood Academic Publisher, London, 1991; pp. 71-109.
58. Peschke E, Peschke D, Hammer T, et al., Influence of melatonin and serotonin on glucose-stimulated insulin release from perifused rat pancreatic islets in vitro. J Pineal Res 1997; 23: 156-163.
59. Peschke E, Peschke D,. Evidence for a circadian rhythm of insulin release from perifused rat pancreatic islets. Diabetologia 1998; 41: 1085-1092.
60. Damiola F, Le Minh N, Preitner N, et al., Restricted feeding uncouples circadian oscillators in peripheral tissues from the central pacemaker in the suprachiasmatic nucleus. Genes Dev 2000; 14: 2950-2961.
61. + permeability in isolated rat islets. Clin Exp Pharmacol Physiol 1999; 26: 505-510.
62. Picinato MC, Haber EP, Carpinelli AR, et al., Daily rhythm of glucose-induced insulin secretion by isolated islets from intact and pinealectomized rat. J Pineal Res 2002; 33: 172-177.
63. Boden G, Chen X, Polansky M,. Disruption of circadian insulin secretion is associated with reduced glucose uptake in first-degree relatives of patients with type 2 diabetes. Diabetes 1999; 48: 2182-2188.
64. Kalsbeek A, Buijs RM,. Output pathways of the mammalian suprachiasmatic nucleus: coding circadian time by transmitter selection and specific targeting. Cell Tissue Res 2002; 309: 109-118.
65. Kalsbeek A, Foppen E, Schalij I, et al., Circadian control of the daily plasma glucose rhythm: an interplay of GABA and glutamate. PLoS ONE 2008; 3: e3194.
66. Peschke E, Stumpf I, Bazwinsky I, et al., Melatonin and type 2 diabetes-a possible link? J Pineal Res 2007; 42: 350-358.
67. Konopka RJ, Benzer S,. Clock mutants of Drosophila melanogaster. Proc Natl Acad Sci U S A 1971; 68: 2112-2116.
68. Reppert SM, Weaver DR,. Coordination of circadian timing in mammals. Nature 2002; 418: 935-941.
69. Dibner C, Schibler U, Albrecht U,. The mammalian circadian timing system: organization and coordination of central and peripheral clocks. Annu Rev Physiol 2010; 72: 517-549.
70. Gekakis N, Staknis D, Nguyen HB, et al., Role of the CLOCK protein in the mammalian circadian mechanism. Science 1998; 280: 1564-1569.
71. Ueda HR, Hayashi S, Chen W, et al., System-level identification of transcriptional circuits underlying mammalian circadian clocks. Nat Genet 2005; 37: 187-192.
72. Yoo SH, Ko CH, Lowrey PL, et al., A noncanonical E-box enhancer drives mouse Period2 circadian oscillations in vivo. Proc Natl Acad Sci U S A 2005; 102: 2608-2613.
73. Ueshima T, Kawamoto T, Honda KK, et al., Identification of a new clock-related element EL-box involved in circadian regulation by BMAL1/CLOCK and HES1. Gene 2012; 510: 118-125.
74. Jetten AM, Kang HS, Takeda Y,. Retinoic acid-related orphan receptors alpha and gamma: key regulators of lipid/glucose metabolism, inflammation, and insulin sensitivity. Front Endocrinol (Lausanne) 2013; 4: 1.
75. Ripperger JA, Schibler U,. Rhythmic CLOCK-BMAL1 binding to multiple E-box motifs drives circadian Dbp transcription and chromatin transitions. Nat Genet 2006; 38: 369-374.
76. Ohno T, Onishi Y, Ishida N,. A novel E4BP4 element drives circadian expression of mPeriod2. Nucleic Acids Res 2007; 35: 648-655.
77. Ralph MR, Menaker M,. A mutation of the circadian system in golden hamsters. Science 1988; 241: 1225-1227.
78. Lowrey PL, Shimomura K, Antoch MP, et al., Positional syntenic cloning and functional characterization of the mammalian circadian mutation tau. Science 2000; 288: 483-492.
79. Doi M, Hirayama J, Sassone-Corsi P,. Circadian regulator CLOCK is a histone acetyltransferase. Cell 2006; 125: 497-508.
80. Balsalobre A, Damiola F, Schibler U,. A serum shock induces circadian gene expression in mammalian tissue culture cells. Cell 1998; 93: 929-937.
81. Welsh DK, Yoo SH, Liu AC, et al., Bioluminescence imaging of individual fibroblasts reveals persistent, independently phased circadian rhythms of clock gene expression. Curr Biol 2004; 14: 2289-2295.
82. Nagoshi E, Brown SA, Dibner C, et al., Circadian gene expression in cultured cells. Methods Enzymol 2005; 393: 543-557.
83. Yoo SH, Yamazaki S, Lowrey PL, et al., PERIOD2:LUCIFERASE real-time reporting of circadian dynamics reveals persistent circadian oscillations in mouse peripheral tissues. Proc Natl Acad Sci U S A 2004; 101: 5339-5346.
84. Kang HS, Angers M, Beak JY, et al., Gene expression profiling reveals a regulatory role for ROR alpha and ROR gamma in phase I and phase II metabolism. Physiol Genomics 2007; 31: 281-294.
85. Kang HS, Okamoto K, Takeda Y, et al., Transcriptional profiling reveals a role for RORalpha in regulating gene expression in obesity-associated inflammation and hepatic steatosis. Physiol Genomics 2011; 43: 818-828.
86. Lau P, Fitzsimmons RL, Pearen MA, et al., Homozygous staggerer (sg/sg) mice display improved insulin sensitivity and enhanced glucose uptake in skeletal muscle. Diabetologia 2011; 54: 1169-1180.
87. Mühlbauer E, Bazwinsky-Wutschke I, Wolgast S, et al., Differential and day-time dependent expression of nuclear receptors RORalpha, RORbeta, RORgamma and RXRalpha in the rodent pancreas and islet. Mol Cell Endocrinol 2013; 365: 129-138.
88. Vriend J, Reiter RJ,. Melatonin feedback on clock genes: a theory involving the proteasome. J Pineal Res 2015; 58: 1-11.
89. Mühlbauer E, Wolgast S, Finckh U, et al., Indication of circadian oscillations in the rat pancreas. FEBS Lett 2004; 564: 91-96.
90. Allaman-Pillet N, Roduit R, Oberson A, et al., Circadian regulation of islet genes involved in insulin production and secretion. Mol Cell Endocrinol 2004; 226: 59-66.
91. Muhlbauer E, Peschke E,. Erg-Kalium-Kanäle in ihrer Rolle als Vermittler circadianer Prozesse der pankreatischen Insel. FEBS Lett 2007; 64: 92-102.
92. Pulimeno P, Mannic T, Sage D, et al., Autonomous and self-sustained circadian oscillators displayed in human islet cells. Diabetologia 2013; 56: 497-507.
93. Sadacca LA, Lamia KA, Delemos AS, et al., An intrinsic circadian clock of the pancreas is required for normal insulin release and glucose homeostasis in mice. Diabetologia 2011; 54: 120-124.
94. Ruiter M, La Fleur SE, Van Heijningen C, et al., The daily rhythm in plasma glucagon concentrations in the rat is modulated by the biological clock and by feeding behavior. Diabetes 2003; 52: 1709-1715.
95. Radziuk J, Pye S,. Diurnal rhythm in endogenous glucose production is a major contributor to fasting hyperglycaemia in type 2 diabetes. Suprachiasmatic deficit or limit cycle behaviour? Diabetologia 2006; 49: 1619-1628.
96. Stokkan KA, Yamazaki S, Tei H, et al., Entrainment of the circadian clock in the liver by feeding. Science 2001; 291: 490-493.
97. Saini C, Liani A, Curie T, et al., Real-time recording of circadian liver gene expression in freely moving mice reveals the phase-setting behavior of hepatocyte clocks. Genes Dev 2013; 27: 1526-1536.
98. Rutter J, Reick M, Wu LC, et al., Regulation of clock and NPAS2 DNA binding by the redox state of NAD cofactors. Science 2001; 293: 510-514.
99. Hirayama J, Sahar S, Grimaldi B, et al., CLOCK-mediated acetylation of BMAL1 controls circadian function. Nature 2007; 450: 1086-1090.
100. + salvage pathway by CLOCK-SIRT1. Science 2009; 324: 654-657.
101. Chang HC, Guarente L,. SIRT1 mediates central circadian control in the SCN by a mechanism that decays with aging. Cell 2013; 153: 1448-1460.
102. Rudic RD, McNamara P, Curtis AM, et al., BMAL1 and CLOCK, two essential components of the circadian clock, are involved in glucose homeostasis. PLoS Biol 2004; 2: e377.
103. Turek FW, Joshu C, Kohsaka A, et al., Obesity and metabolic syndrome in circadian Clock mutant mice. Science 2005; 308: 1043-1045.
104. Lamia KA, Storch KF, Weitz CJ,. Physiological significance of a peripheral tissue circadian clock. Proc Natl Acad Sci U S A 2008; 105: 15172-15177.
105. Hofmann K, Schonerstedt U, Muhlbauer E, et al., Clock gene expression in the liver of streptozotocin-induced and spontaneous type 1 diabetic rats. Horm Metab Res 2013; 45: 629-639.
106. Lee J, Kim MS, Li R, et al., Loss of Bmal1 leads to uncoupling and impaired glucose-stimulated insulin secretion in beta-cells. Islets 2011; 3: 381-388.
107. Marcheva B, Ramsey KM, Buhr ED, et al., Disruption of the clock components CLOCK and BMAL1 leads to hypoinsulinaemia and diabetes. Nature 2010; 466: 627-631.
108. Gale JE, Cox HI, Qian J, et al., Disruption of circadian rhythms accelerates development of diabetes through pancreatic beta-cell loss and dysfunction. J Biol Rhythms 2011; 26: 423-433.
109. Hofmann K, Schonerstedt U, Muhlbauer E, et al., Clock gene expression in the liver of streptozotocin-induced and spontaneous type 1 diabetic rats. Horm Metab Res 2013; 45: 629-639.
110. Stamenkovic JA, Olsson AH, Nagorny CL, et al., Regulation of core clock genes in human islets. Metabolism 2012; 61: 978-985.
111. Englund A, Kovanen L, Saarikoski ST, et al., NPAS2 and PER2 are linked to risk factors of the metabolic syndrome. J Circadian Rhythms 2009; 7: 5.
112. Scheer FA, Hilton MF, Mantzoros CS, et al., Adverse metabolic and cardiovascular consequences of circadian misalignment. Proc Natl Acad Sci U S A 2009; 106: 4453-4458.
113. Van Cauter E, Blackman JD, Roland D, et al., Modulation of glucose regulation and insulin secretion by circadian rhythmicity and sleep. J Clin Invest 1991; 88: 934-942.
114. Brown SA, Fleury-Olela F, Nagoshi E, et al., The period length of fibroblast circadian gene expression varies widely among human individuals. PLoS Biol 2005; 3: e338.
115. Reppert SM, Weaver DR, Ebisawa T,. Cloning and characterization of a mammalian melatonin receptor that mediates reproductive and circadian responses. Neuron 1994; 13: 1177-1185.
116. Reppert SM, Godson C, Mahle CD, et al., Molecular characterization of a second melatonin receptor expressed in human retina and brain: the Mel1b melatonin receptor. Proc Natl Acad Sci U S A 1995; 92: 8734-8738.
117. Lyssenko V, Nagorny CL, Erdos MR, et al., Common variant in MTNR1B associated with increased risk of type 2 diabetes and impaired early insulin secretion. Nat Genet 2009; 41: 82-88.
118. Prokopenko I, Langenberg C, Florez JC, et al., Variants in MTNR1B influence fasting glucose levels. Nat Genet 2009; 41: 77-81.
119. Nagorny CLF, Sathanoori R, Voss U, et al., Distribution of melatonin receptors in murine pancreatic islets. J Pineal Res 2011; 50: 412-417.
120. Bouatia-Naji N, Bonnefond A, Cavalcanti-Proenca C, et al., A variant near MTNR1B is associated with increased fasting plasma glucose levels and type 2 diabetes risk. Nat Genet 2009; 41: 89-94.
121. Ramracheya RD, Muller DS, Squires PE, et al., Function and expression of melatonin receptors on human pancreatic islets. J Pineal Res 2008; 44: 273-279.
122. Liu C, Weaver DR, Jin X, et al., Molecular dissection of two distinct actions of melatonin on the suprachiasmatic circadian clock. Neuron 1997; 19: 91-102.
123. Jin X, Von Gall C, Pieschl RL, et al., Targeted disruption of the mouse Mel(1b) melatonin receptor. Mol Cell Biol 2003; 23: 1054-1060.
124. Picinato MC, Haber EP, Cipolla-Neto J, et al., Melatonin inhibits insulin secretion and decreases PKA levels without interfering with glucose metabolism in rat pancreatic islets. J Pineal Res 2002; 33: 156-160.
125. Tasali E, Leproult R, Ehrmann DA, et al., Slow-wave sleep and the risk of type 2 diabetes in humans. Proc Natl Acad Sci U S A 2008; 105: 1044-1049.
126. Braun M, Ramracheya R, Johnson PR, et al., Exocytotic properties of human pancreatic ß-cells. Ann N Y Acad Sci 2009; 1152: 187-193.
127. Tengholm A, Gylfe E,. Oscillatory control of insulin secretion. Mol Cell Endocrinol 2009; 297: 58-72.
128. Mears D,. Regulation of insulin secretion in islets of Langerhans by Ca(2+)channels. J Membr Biol 2004; 200: 57-66.
129. Muhlbauer E, Albrecht E, Bazwinsky-Wutschke I, et al., Melatonin influences insulin secretion primarily via MT(1) receptors in rat insulinoma cells (INS-1) and mouse pancreatic islets. J Pineal Res 2012; 52: 446-459.
130. Stumpf I, Bazwinsky I, Peschke E,. Modulation of the cGMP signaling pathway by melatonin in pancreatic beta-cells. J Pineal Res 2009; 46: 140-147.
131. Brydon L, Petit L, Delagrange P, et al., Functional expression of MT2 (Mel1b) melatonin receptors in human PAZ6 adipocytes. Endocrinology 2001; 142: 4264-4271.
132. Mühlbauer E, Albrecht E, Hofmann K, et al., Melatonin inhibits insulin secretion in rat insulinoma beta-cells (INS-1) heterologously expressing the human melatonin receptor isoform MT2. J Pineal Res 2011; 51: 361-372.
133. Bazwinsky-Wutschke I, Mühlbauer E, Peschke E,. Calcium signaling components and phosphorylation of cyclic AMP-response element-binding protein (CREB) are influenced by melatonin in pancreatic β-cells. Abh Sächs Akad Wiss Math-Nat Kl 2014; 66: 89-100.
134. Bazwinsky-Wutschke I, Wolgast S, Muhlbauer E, et al., Phosphorylation of cyclic AMP-response element-binding protein (CREB) is influenced by melatonin treatment in pancreatic rat insulinoma beta-cells (INS-1). J Pineal Res 2012; 53: 344-357.
135. Bazwinsky-Wutschke I, Muhlbauer E, Wolgast S, et al., Transcripts of calcium/calmodulin-dependent kinases are changed after forskolin- or IBMX-induced insulin secretion due to melatonin treatment of rat insulinoma beta-cells (INS-1). Horm Metab Res 2009; 41: 805-813.
136. Bazwinsky-Wutschke I, Muhlbauer E, Albrecht E, et al., Calcium-signaling components in rat insulinoma beta-cells (INS-1) and pancreatic islets are differentially influenced by melatonin. J Pineal Res 2014; 56: 439-449.
137. Bazwinsky-Wutschke I, Bieseke L, Muhlbauer E, et al., Influence of melatonin receptor signalling on parameters involved in blood glucose regulation. J Pineal Res 2014; 56: 82-96.
138. Furstenau U, Schwaninger M, Blume R, et al., Characterization of a novel calcium response element in the glucagon gene. J Biol Chem 1999; 274: 5851-5860.
139. Oetjen E, Grapentin D, Blume R, et al., Regulation of human insulin gene transcription by the immunosuppressive drugs cyclosporin A and tacrolimus at concentrations that inhibit calcineurin activity and involving the transcription factor CREB. Naunyn Schmiedebergs Arch Pharmacol 2003; 367: 227-236.
140. Sander M, German MS,. The beta cell transcription factors and development of the pancreas. J Mol Med (Berl) 1997; 75: 327-340.
141. Bazwinsky-Wutschke I, Wolgast S, Muhlbauer E, et al., Distribution patterns of calcium-binding proteins in pancreatic tissue of non-diabetic as well as type 2 diabetic rats and in rat insulinoma beta-cells (INS-1). Histochem Cell Biol 2010; 134: 115-127.
142. Gagliardino JJ, Pessacq MT, Hernandez RE, et al., Circadian variations in serum glucagon and hepatic glycogen and cyclic amp concentrations. J Endocrinol 1978; 78: 297-298.
143. Tasaka Y, Inoue S, Maruno K, et al., Twenty-four-hour variations of plasma pancreatic polypeptide, insulin and glucagon in normal human subjects. Endocrinol Jpn 1980; 27: 495-498.
144. Yamamoto H, Nagai K, Nakagawa H,. Role of SCN in daily rhythms of plasma glucose, FFA, insulin and glucagon. Chronobiol Int 1987; 4: 483-491.
145. Kosa E, Maurel D, Siaud P,. Effects of pinealectomy on glucagon responsiveness to hypoglycaemia induced by insulin injections in fed rats. Exp Physiol 2001; 86: 617-620.
146. Bähr I, Mühlbauer E, Schucht H, et al., Melatonin stimulates glucagon secretion in vitro and in vivo. J Pineal Res 2011; 50: 336-344.
147. Bahr I, Muhlbauer E, Albrecht E, et al., Evidence of the receptor-mediated influence of melatonin on pancreatic glucagon secretion via the Galphaq protein-coupled and PI3K signaling pathways. J Pineal Res 2012; 53: 390-398.
148. New DC, Tsim ST, Wong YH,. G protein-linked effector and second messenger systems involved in melatonin signal transduction. Neurosignals 2003; 12: 59-70.
149. Peschke E, Bahr I, Muhlbauer E,. Melatonin and pancreatic islets: interrelationships between melatonin, insulin and glucagon. Int J Mol Sci 2013; 14: 6981-7015.
150. Peschke E, Schucht H, Muhlbauer E,. Long-term enteral administration of melatonin reduces plasma insulin and increases expression of pineal insulin receptors in both Wistar and type 2-diabetic Goto-Kakizaki rats. J Pineal Res 2010; 49: 373-381.
151. Ward WK, Bolgiano DC, McKnight B, et al., Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus. J Clin Invest 1984; 74: 1318-1328.
152. Cryer PE,. Hypoglycaemia: the limiting factor in the glycaemic management of Type I and Type II diabetes. Diabetologia 2002; 45: 937-948.
153. Burcelin R, Knauf C, Cani PD,. Pancreatic alpha-cell dysfunction in diabetes. Diabetes Metab 2008; 34 (Suppl 2): S49-S55.
154. Quesada I, Tuduri E, Ripoll C, et al., Physiology of the pancreatic alpha-cell and glucagon secretion: role in glucose homeostasis and diabetes. J Endocrinol 2008; 199: 5-19.
155. Staiger H, Machicao F, Schafer SA, et al., Polymorphisms within the novel type 2 diabetes risk locus MTNR1B determine beta-cell function. PLoS ONE 2008; 3: e3962.
156. Li C, Shi Y, You L, et al., Melatonin receptor 1A gene polymorphism associated with polycystic ovary syndrome. Gynecol Obstet Invest 2011; 72: 130-134.
157. Cabrera O, Berman DM, Kenyon NS, et al., The unique cytoarchitecture of human pancreatic islets has implications for islet cell function. Proc Natl Acad Sci U S A 2006; 103: 2334-2339.
158. Schmid SM, Hallschmid M, Jauch-Chara K, et al., Sleep loss alters basal metabolic hormone secretion and modulates the dynamic counterregulatory response to hypoglycemia. J Clin Endocrinol Metab 2007; 92: 3044-3051.
159. Schmid SM, Jauch-Chara K, Hallschmid M, et al., Mild sleep restriction acutely reduces plasma glucagon levels in healthy men. J Clin Endocrinol Metab 2009; 94: 5169-5173.
160. Gottlieb DJ, Punjabi NM, Newman AB, et al., Association of sleep time with diabetes mellitus and impaired glucose tolerance. Arch Intern Med 2005; 165: 863-867.
161. Donga E, Van Dijk M, Van Dijk JG, et al., A single night of partial sleep deprivation induces insulin resistance in multiple metabolic pathways in healthy subjects. J Clin Endocrinol Metab 2010; 95: 2963-2968.
162. Yaggi HK, Araujo AB, McKinlay JB,. Sleep duration as a risk factor for the development of type 2 diabetes. Diabetes Care 2006; 29: 657-661.
163. Nadal A, Quesada I, Soria B,. Homologous and heterologous asynchronicity between identified alpha-, beta- and delta-cells within intact islets of Langerhans in the mouse. J Physiol 1999; 517 (Pt 1): 85-93.
164. Braun M, Ramracheya R, Amisten S, et al., Somatostatin release, electrical activity, membrane currents and exocytosis in human pancreatic delta cells. Diabetologia 2009; 52: 1566-1578.
165. Hauge-Evans AC, King AJ, Carmignac D, et al., Somatostatin secreted by islet delta-cells fulfills multiple roles as a paracrine regulator of islet function. Diabetes 2009; 58: 403-411.
166. Hauge-Evans AC, King AJ, Fairhall K, et al., A role for islet somatostatin in mediating sympathetic regulation of glucagon secretion. Islets 2010; 2: 341-344.
167. Hellman B, Salehi A, Gylfe E, et al., Glucose generates coincident insulin and somatostatin pulses and antisynchronous glucagon pulses from human pancreatic islets. Endocrinology 2009; 150: 5334-5340.
168. Wang HM, Dong JH, Li Q, et al., A stress response pathway in mice upregulates somatostatin level and transcription in pancreatic delta cells through Gs and beta-arrestin 1. Diabetologia 2014; 57: 1899-1910.
169. Zibolka J, Mühlbauer E, Peschke E,. The human somatostatinoma cell line QGP-1 as a model for functional, melatonin-responsive islet d-cells. Abh Sächs Akad Wiss Math-Nat Kl 2014; 66: 73-78.
170. Zibolka J, Muhlbauer E, Peschke E,. Melatonin influences somatostatin secretion from human pancreatic delta-cells via MT1 and MT2 receptors. J Pineal Res 2015; 58: 198-209.
171. Browning C, Beresford I, Fraser N, et al., Pharmacological characterization of human recombinant melatonin mt(1) and MT(2) receptors. Br J Pharmacol 2000; 129: 877-886.
172. Godson C, Reppert SM,. The Mel1a melatonin receptor is coupled to parallel signal transduction pathways. Endocrinology 1997; 138: 397-404.
173. Brydon L, Roka F, Petit L, et al., Dual signaling of human Mel1a melatonin receptors via G(i2), G(i3), and G(q/11) proteins. Mol Endocrinol 1999; 13: 2025-2038.
174. Blumenau C, Berger E, Fauteck JD, et al., Expression and functional characterization of the mt1 melatonin receptor from rat brain in Xenopus oocytes: evidence for coupling to the phosphoinositol pathway. J Pineal Res 2001; 30: 139-146.
175. Ross AW, Webster CA, Thompson M, et al., A novel interaction between inhibitory melatonin receptors and protein kinase C-dependent signal transduction in ovine pars tuberalis cells. Endocrinology 1998; 139: 1723-1730.
176. Jarzynka MJ, Passey DK, Ignatius PF, et al., Modulation of melatonin receptors and G-protein function by microtubules. J Pineal Res 2006; 41: 324-336.
177. Brydon L, Petit L, De Coppet P, et al., Polymorphism and signalling of melatonin receptors. Reprod Nutr Dev 1999; 39: 315-324.
178. Mackenzie RS, Melan MA, Passey DK, et al., Dual coupling of MT(1) and MT(2) melatonin receptors to cyclic AMP and phosphoinositide signal transduction cascades and their regulation following melatonin exposure. Biochem Pharmacol 2002; 63: 587-595.
179. Witt-Enderby PA, Masana MI, Dubocovich ML,. Physiological exposure to melatonin supersensitizes the cyclic adenosine 3′,5′-monophosphate-dependent signal transduction cascade in Chinese hamster ovary cells expressing the human mt1 melatonin receptor. Endocrinology 1998; 139: 3064-3071.
180. Shiu SY, Pang B, Tam CW, et al., Signal transduction of receptor-mediated antiproliferative action of melatonin on human prostate epithelial cells involves dual activation of Galpha(s) and Galpha(q) proteins. J Pineal Res 2010; 49: 301-311.
181. Picinato MC, Hirata AE, Cipolla-Neto J, et al., Activation of insulin and IGF-1 signaling pathways by melatonin through MT1 receptor in isolated rat pancreatic islets. J Pineal Res 2008; 44: 88-94.
182. Anhe GF, Caperuto LC, Pereira-Da-Silva M, et al., In vivo activation of insulin receptor tyrosine kinase by melatonin in the rat hypothalamus. J Neurochem 2004; 90: 559-566.
183. Reppert SM, Weaver DR, Cassone VM, et al., Melatonin receptors are for the birds: molecular analysis of two receptor subtypes differentially expressed in chick brain. Neuron 1995; 15: 1003-1015.
184. Vanecek J,. Cellular mechanisms of melatonin action. Physiol Rev 1998; 78: 687-721.
185. Simonneaux V, Ribelayga C,. Generation of the melatonin endocrine message in mammals: a review of the complex regulation of melatonin synthesis by norepinephrine, peptides, and other pineal transmitters. Pharmacol Rev 2003; 55: 325-395.
186. Peschke E,. Zum Einfluss von Melatonin auf Insulinsekretion, Signaltransduktion und Sekretionsrhythmus pankreatischer B-Zellen in vitro. Abh Sächs Akad Wiss Math-Nat Kl 2003; 60: 89-119.
187. Peschke E,. Über den phylogenetischen Funktionswandel des Pinealorgans und seine Bedeutung für die Insulinsekretion bei Mammalia. Sitzungsber Sächs Akad Wiss Math-Nat Kl 2004; 129: 1-34.
188. Nakada S, Ishikawa T, Yamamoto Y, et al., Constitutive nitric oxide synthases in rat pancreatic islets: direct imaging of glucose-induced nitric oxide production in beta-cells. Pflugers Arch 2003; 447: 305-311.
189. Lajoix AD, Reggio H, Chardes T, et al., A neuronal isoform of nitric oxide synthase expressed in pancreatic beta-cells controls insulin secretion. Diabetes 2001; 50: 1311-1323.
190. Kaminski A, Gao H, Morgan NG,. Involvement of the cGMP signalling pathway in the regulation of viability in insulin-secreting BRIN-BD11 cells. FEBS Lett 2004; 559: 118-124.
191. Storling J, Binzer J, Andersson AK, et al., Nitric oxide contributes to cytokine-induced apoptosis in pancreatic beta cells via potentiation of JNK activity and inhibition of Akt. Diabetologia 2005; 48: 2039-2050.
192. Laychock SG, Modica ME, Cavanaugh CT,. L-arginine stimulates cyclic guanosine 3′,5′-monophosphate formation in rat islets of Langerhans and RINm5F insulinoma cells: evidence for L-arginine:nitric oxide synthase. Endocrinology 1991; 129: 3043-3052.
193. 2+ concentration in rat pancreatic beta-cells. Life Sci 1999; 65: 1515-1522.
194. 2+ concentration and insulin secretion in rat pancreatic beta-cells. Am J Physiol Cell Physiol 2003; 284: C1215-C1222.
195. Petit L, Lacroix I, De Coppet P, et al., Differential signaling of human Mel1a and Mel1b melatonin receptors through the cyclic guanosine 3′-5′-monophosphate pathway. Biochem Pharmacol 1999; 58: 633-639.
196. Ayoub MA, Levoye A, Delagrange P, et al., Preferential formation of MT1/MT2 melatonin receptor heterodimers with distinct ligand interaction properties compared with MT2 homodimers. Mol Pharmacol 2004; 66: 312-321.
197. Levoye A, Jockers R, Ayoub MA, et al., Are G protein-coupled receptor heterodimers of physiological relevance?-Focus on melatonin receptors. Chronobiol Int 2006; 23: 419-426.
198. Zwiller J, Revel MO, Basset P,. Evidence for phosphorylation of rat brain guanylate cyclase by cyclic AMP-dependent protein kinase. Biochem Biophys Res Commun 1981; 101: 1381-1387.
199. Peschke E, Mühlbauer E,. New evidence for a role of melatonin in glucose regulation. Best Pract Res Clin Endocrinol Metab 2010; 24: 829-841.
200. Faillace MP, Keller Sarmiento MI, Rosenstein RE,. Melatonin effect on the cyclic GMP system in the golden hamster retina. Brain Res 1996; 711: 112-117.
201. Ferreyra GA, Golombek DA,. Rhythmicity of the cGMP-related signal transduction pathway in the mammalian circadian system. Am J Physiol Regul Integr Comp Physiol 2001; 280: R1348-R1355.
202. Peschke E,. Melatonin, endocrine pancreas and diabetes. J Pineal Res 2008; 44: 26-40.
203. Popova JS, Dubocovich ML,. Melatonin receptor-mediated stimulation of phosphoinositide breakdown in chick brain slices. J Neurochem 1995; 64: 130-138.
204. Zemkova H, Vanecek J,. Differences in gonadotropin-releasing hormone-induced calcium signaling between melatonin-sensitive and melatonin-insensitive neonatal rat gonadotrophs. Endocrinology 2000; 141: 1017-1026.
205. Balik A, Kretschmannova K, Mazna P, et al., Melatonin action in neonatal gonadotrophs. Physiol Res 2004; 53 (Suppl 1): S153-S166.
206. Girouard H, De Champlain J,. Inhibitory effect of melatonin on alpha1-adrenergic-induced vasoconstriction in mesenteric beds of spontaneously hypertensive rats. Am J Hypertens 2004; 17: 339-346.
207. 2+ release from INS1 insulinoma cells. J Pineal Res 2005; 39: 316-323.
208. Bach AG, Peschke E,. Melatonin and type 2 diabetes. In: Melatonin in the Promotion of Health, 2nd edn., Watson RR, ed., CRC Press, Taylor and Francis Group, Boca Raton, FL, 2012; pp. 147-165.
209. Lai FP, Mody SM, Yung LY, et al., Chimeric Galphaq subunits can distinguish the long form of the Xenopus Mel1c melatonin receptor from the mammalian mt1 and MT2 melatonin receptors. J Pineal Res 2001; 30: 171-179.
210. Lai FP, Mody SM, Yung LY, et al., Molecular determinants for the differential coupling of Galpha(16) to the melatonin MT1, MT2 and Xenopus Mel1c receptors. J Neurochem 2002; 80: 736-745.
211. Mulder H, Nagorny CL, Lyssenko V, et al., Melatonin receptors in pancreatic islets: good morning to a novel type 2 diabetes gene. Diabetologia 2009; 52: 1240-1249.
212. Van Cauter E,. Putative roles of melatonin in glucose regulation. Therapie 1998; 53: 467-472.
213. Peschke D, Peschke E, Mess B,. Circannual rhythm and increase of body weight and food intake in the young Wistar-rat following pinealectomy and ganglionectomy. Neuro Endocrinol Lett 1987; 9: 321-327.
214. Peschke E, Frese T, Chankiewitz E, et al., Diabetic Goto Kakizaki rats as well as type 2 diabetic patients show a decreased diurnal serum melatonin level and an increased pancreatic melatonin-receptor status. J Pineal Res 2006; 40: 135-143.
215. Murialdo G, Costelli P, Fonzi S, et al., Circadian secretion of melatonin and thyrotropin in hospitalized aged patients. Aging (Milano) 1993; 5: 39-46.
216. Reiter RJ,. Oxidative damage in the central nervous system: protection by melatonin. Prog Neurobiol 1998; 56: 359-384.
217. Tarquini B, Cornelissen G, Perfetto F, et al., Chronome assessment of circulating melatonin in humans. In Vivo 1997; 11: 473-484.
218. Morgan L, Hampton S, Gibbs M, et al., Circadian aspects of postprandial metabolism. Chronobiol Int 2003; 20: 795-808.
219. Qin LQ, Li J, Wang Y, et al., The effects of nocturnal life on endocrine circadian patterns in healthy adults. Life Sci 2003; 73: 2467-2475.
220. Ribeiro DC, Hampton SM, Morgan L, et al., Altered postprandial hormone and metabolic responses in a simulated shift work environment. J Endocrinol 1998; 158: 305-310.
221. Robeva R, Kirilov G, Tomova A, et al., Low testosterone levels and unimpaired melatonin secretion in young males with metabolic syndrome. Andrologia 2006; 38: 216-220.
222. Frese T, Bach AG, Muhlbauer E, et al., Pineal melatonin synthesis is decreased in type 2 diabetic Goto-Kakizaki rats. Life Sci 2009; 85: 526-533.
223. Peschke E, Bach AG, Muhlbauer E,. Parallel signaling pathways of melatonin in the pancreatic beta-cell. J Pineal Res 2006; 40: 184-191.
224. Peschke E, Stumpf I, Mühlbauer E,. Rezeptor vermittelte Einflüsse von Melatonin auf die second messenger cAMP, cGMP und IP3 pankreatischer b-Zellen sowie Insulin-Melatonin-Interaktionen. Abh Sächs Akad Wissensch Leipzig 2009; 65: 45-62.
225. Bach AG, Mühlbauer E, Peschke E,. Adrenoceptor expression and diurnal rhythms of melatonin and its precursors in the pineal gland of type 2 diabetic Goto-Kakizaki rats. Endocrinology 2010; 151: 2483-2493.
226. Peschke E, Hofmann K, Ponicke K, et al., Catecholamines are the key for explaining the biological relevance of insulin-melatonin antagonisms in type 1 and type 2 diabetes. J Pineal Res 2012; 52: 389-396.
227. Peschke E, Wolgast S, Bazwinsky I, et al., Increased melatonin synthesis in pineal glands of rats in streptozotocin induced type 1 diabetes. J Pineal Res 2008; 45: 439-448.
228. Nishida S, Segawa T, Murai I, et al., Long-term melatonin administration reduces hyperinsulinemia and improves the altered fatty-acid compositions in type 2 diabetic rats via the restoration of Delta-5 desaturase activity. J Pineal Res 2002; 32: 26-33.
229. Nishida S,. Metabolic effects of melatonin on oxidative stress and diabetes mellitus. Endocrine 2005; 27: 131-136.
230. Bojkova B, Orendas P, Friedmanova L, et al., Prolonged melatonin administration in 6-month-old Sprague-Dawley rats: metabolic alterations. Acta Physiol Hung 2008; 95: 65-76.
231. Nishida S, Sato R, Murai I, et al., Effect of pinealectomy on plasma levels of insulin and leptin and on hepatic lipids in type 2 diabetic rats. J Pineal Res 2003; 35: 251-256.
232. Peschke E, Hofmann K, Bahr I, et al., The insulin-melatonin antagonism: studies in the LEW.1AR1-iddm rat (an animal model of human type 1 diabetes mellitus). Diabetologia 2011; 54: 1831-1840.
233. Ahren B,. Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes. Nat Rev Drug Discov 2009; 8: 369-385.
234. Ahrén B,. GLP-1 for type 2 diabetes. Exp Cell Res 2011; 317: 1239-1245.
235. Saunders C, Limbird LE,. Localization and trafficking of alpha2-adrenergic receptor subtypes in cells and tissues. Pharmacol Ther 1999; 84: 193-205.
236. Klein DC,. Arylalkylamine N-acetyltransferase: "the Timezyme". J Biol Chem 2007; 282: 4233-4237.
237. Arendt J,. Importance and relevance of melatonin to human biological rhythms. J Neuroendocrinol 2003; 15: 427-431.
238. Korf HW, Schomerus C, Stehle JH,. The pineal organ, its hormone melatonin, and the photoneuroendocrine system. Adv Anat Embryol Cell Biol 1998; 146: 1-100.
239. Korf HW, Stehle JH,. The circadian system: circuits-cells-clock genes. Cell Tissue Res 2002; 309: 1-2.
240. Reiter RJ, Paredes SD, Manchester LC, et al., Reducing oxidative/nitrosative stress: a newly-discovered genre for melatonin. Crit Rev Biochem Mol Biol 2009; 44: 175-200.
241. Lenzen S,. Oxidative stress: the vulnerable beta cell. Biochem Soc Trans 2008; 36: 343-347.
242. Simonis-Bik AM, Nijpels G, Van Haeften TW, et al., Gene variants in the novel type 2 diabetes loci CDC123/CAMK1D, THADA, ADAMTS9, BCL11A, and MTNR1B affect different aspects of pancreatic beta-cell function. Diabetes 2010; 59: 293-301.
243. Chambers JC, Zhang W, Zabaneh D, et al., Common genetic variation near melatonin receptor MTNR1B contributes to raised plasma glucose and increased risk of type 2 diabetes among Indian Asians and European Caucasians. Diabetes 2009; 58: 2703-2708.
244. Olsson L, Pettersen E, Ahlbom A, et al., No effect by the common gene variant rs10830963 of the melatonin receptor 1B on the association between sleep disturbances and type 2 diabetes: results from the Nord-Trondelag Health Study. Diabetologia 2011; 54: 1375-1378.
245. Andersson EA, Holst B, Sparso T, et al., MTNR1B G24E variant associates with BMI and fasting plasma glucose in the general population in studies of 22,142 Europeans. Diabetes 2010; 59: 1539-1548.
246. Bonnefond A, Clement N, Fawcett K, et al., Rare MTNR1B variants impairing melatonin receptor 1B function contribute to type 2 diabetes. Nat Genet 2012; 44: 297-301.
247. Lenzen S, Panten U,. Alloxan: history and mechanism of action. Diabetologia 1988; 31: 337-342.
248. Bromme HJ, Ebelt H, Peschke D, et al., Alloxan acts as a prooxidant only under reducing conditions: influence of melatonin. Cell Mol Life Sci 1999; 55: 487-493.
249. Gorus FK, Malaisse WJ, Pipeleers DG,. Selective uptake of alloxan by pancreatic B-cells. Biochem J 1982; 208: 313-315.
250. Malaisse WJ, Malaisse-Lagae F, Sener A, et al., Determinants of the selective toxicity of alloxan to the pancreatic B cell. Proc Natl Acad Sci USA 1982; 79: 927-930.
251. Bromme HJ, Morke W, Peschke D, et al., Scavenging effect of melatonin on hydroxyl radicals generated by alloxan. J Pineal Res 2000; 29: 201-208.
252. Brömme HJ, Peschke E,. Molekulare Mechanismen der Alloxan-Toxizität sowie die radikalfangende und antidiabetogene Bedeutung von Melatonin. Abh Sächs Akad Wiss Math-Nat Kl 2003; 60: 137-162.
253. Ebelt H, Peschke D, Bromme HJ, et al., Influence of melatonin on free radical-induced changes in rat pancreatic beta-cells in vitro. J Pineal Res 2000; 28: 65-72.
254. Peschke E, Ebelt H, Brömme HJ, et al., 'Classical' and 'new' diabetogens-comparison of their effects on isolated rat pancreatic islets in vitro. Cell Mol Life Sci 2000; 57: 158-164.
255. Poeggeler B, Reiter RJ, Tan DX, et al., Melatonin, hydroxyl radical-mediated oxidative damage, and aging: a hypothesis. J Pineal Res 1993; 14: 151-168.
256. Reiter RJ,. Antioxidant actions of melatonin. Adv Pharmacol 1997; 38: 103-117.
257. Reiter RJ, Carneiro RC, Oh CS,. Melatonin in relation to cellular antioxidative defense mechanisms. Horm Metab Res 1997; 29: 363-372.
258. Marshall KA, Reiter RJ, Poeggeler B, et al., Evaluation of the antioxidant activity of melatonin in vitro. Free Radic Biol Med 1996; 21: 307-315.